Quoted Micro 26 January 2026

AQUIS STOCK EXCHANGE Cardiometabolic health products developer ProBiotix Health (PBX) increased sales by 45% to £2.72m in 2025 and reduced the loss. During the year, ProBiotix entered the Korean market and submitted applications for two new clinical trials. There was £1.27m in the bank at the end of £1.27m. The order book is worth £1.3m. […]

Quoted Micro 17 June 2024

AQUIS STOCK EXCHANGE Samarkand (SMK) has sold its probiotic brand of Probio7 for £1.3m with an initial cash payment of £1.1m. This will provide working capital for the company’s other healthcare brands. Unsecured loans made by the directors to finance the acquisition of Optimised Energetics will be repaid. Skin treatments developer Incanthera (INC) has moved […]